Jenscare Scientific Co., Ltd., a structural heart disease intervention device maker based in Ningbo, is set to make an initial public offering (IPO) of 8.08 million shares on the Hong Kong Stock Exchange. The IPO is priced at HKD 28.8 ($3.67) per share, raising a total of HKD 232.6 million.
Company Overview and Core Products
Founded in 2011, Jenscare provides a range of treatment solutions for different types of structural heart disease, including tricuspid valve disease, aortic valve disease, mitral valve disease, and heart failure. The company’s core product, LuX-Valve, is a first-generation transcatheter tricuspid valve replacement (TTR) system designed for patients with severe tricuspid regurgitation and high surgical risk. Another core product, Ken-Valve, is designed for the treatment of severe aortic valve regurgitation (or combined aortic valve stenosis), addressing patient needs beyond those of transcatheter aortic valve replacement solely for the treatment of aortic valve stenosis.
Use of Proceeds
The proceeds from the IPO will be used to fund R&D, manufacturing, and commercialization of core products LuX-Valve and Ken-Valve. This includes continuing R&D, clinical studies, regulatory filings, and commercialization efforts for these products, as well as R&D, clinical studies, and regulatory filings for other product pipelines. The funds will also support working capital.
Financial Performance
Jenscare recorded a net loss of RMB 500.7 million ($70.5 million) in 2021 and RMB 73.5 million ($10.3 million) in the first six months of 2022, primarily due to R&D and administrative expenses. Despite the losses, the company’s net assets surged to RMB 1.29 billion ($181.6 million) in 2021 from RMB 352.8 million ($49.6 million) in 2020.
Future Outlook
The IPO marks a significant step for Jenscare as it seeks to expand its capabilities in structural heart disease intervention. With the funds raised, the company is well-positioned to advance its core products and pipeline, ultimately contributing to improved treatment options for patients with complex heart conditions.-Fineline Info & Tech
